Clinical Oncology
Volume 20, Issue 7 , Pages 517-522 , September 2008

Use of Imatinib Mesylate in Gastrointestinal Stromal Tumours: Pan-Birmingham Cancer Network Experience

  • D.W.Y. Wong

      Affiliations

    • The Cancer Centre, Queen Elizabeth Medical Centre, Birmingham, UK
    • ,
  • S.C. Lupton

      Affiliations

    • The Cancer Centre, Queen Elizabeth Medical Centre, Birmingham, UK
    • ,
  • L. Bhatt

      Affiliations

    • The Cancer Centre, Queen Elizabeth Medical Centre, Birmingham, UK
    • ,
  • L. Gross

      Affiliations

    • CRUK Clinical Trials Unit, University of Birmingham, Edgbaston, UK
    • ,
  • P. Tanière

      Affiliations

    • Department of Pathology, Queen Elizabeth Medical Centre, Birmingham, UK
    • ,
  • D.R. Peake

      Affiliations

    • The Cancer Centre, Queen Elizabeth Medical Centre, Birmingham, UK
    • ,
  • D. Spooner

      Affiliations

    • The Cancer Centre, Queen Elizabeth Medical Centre, Birmingham, UK
    • ,
  • J.I. Geh

      Affiliations

    • The Cancer Centre, Queen Elizabeth Medical Centre, Birmingham, UK
    • Corresponding Author InformationAuthor for correspondence: J. I. Geh, Queen Elizabeth Hospital, Department of Clinical Oncology, Metchley Park Road, Birmingham B15 2TH, UK. Tel: +44-121-627-2379.

Received 25 October 2007 ,Revised 31 March 2008 ,Accepted 1 April 2008.

References 

  1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269
  2. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumours. Am J Pathol. 2000;156:791–795
  3. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol. 2002;33:459–465
  4. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the pre-imatinib mesylate era. Cancer. 2005;103:821–829
  5. Reid R, Bulusu R, Buckels J, et al. Guidelines for the management of gastrointestinal stromal tumours (GISTs). Novartis Oncology. April 2006.
  6. Dematteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58
  7. Dematteo RP, Heinrich MC, El-Riffai WM, Dimetri G. Clinical management of gastrointestinal stromal tumours: before and after STI571. Hum Pathol. 2002;33:466–477
  8. Miettinen M, Makhlouf H, Sobin L, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–489
  9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:471–480
  10. Blanke CD, Demetri GD, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–625
  11. National Institute for Health and Clinical Excellence. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours. October 2004.
  12. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566–578
  13. National Institute for Health and Clinical Excellence. Improving outcomes for people with sarcoma – Cancer Service Guidance. March 2006.
  14. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  15. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134
  16. Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33(5):478–483
  17. O'Sullivan B, Deshmukh N, Reynolds G, et al. Retrospective analysis of GIST in one regional UK reference centre. Gut. 2007;56:A7
  18. Heinrich MC, Corless CL, Duensing A, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349
  19. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093–1103
  20. Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol. 2006;79:e40–e44
  21. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45(3):357–365
  22. Bauer S, Hartmann JT, de Wit M. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117(2):316–325
  23. Hasegawa J, Kanda T, Hirota S, et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol. 2007;12(3):212–217
  24. Salmons N, Gregg RJ, Pallalau A, et al. Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib. J Clin Pathol. 2007;60:199–201
  25. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer. 2005;41:1751–1757
  26. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338
  27. Heinrich MC, Maki RG, Corless CL, et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006;24(18S):9502
  28. Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004;53:235–240

PII: S0936-6555(08)00209-4

doi: 10.1016/j.clon.2008.04.008

Clinical Oncology
Volume 20, Issue 7 , Pages 517-522 , September 2008

Article Tools

* Image Usage & Resolution